 PDL BioPharma NASDAQ:PDLI was upgraded by equities research analysts at ValuEngine from a hold rating to a buy rating in a note issued to investors on Tuesday, ValuEngine reports. Several other equities analysts have also issued reports on the company. Zacks Investment Research lowered PDL BioPharma from a strong-buy rating to a hold rating and ... 